#### perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 1 Morning exercise and pre-breakfast metformin interact to reduce glycaemia in people 2 with Type 2 Diabetes: a randomized crossover trial

Brenda J. Pena Carrillo<sup>1, 2</sup>, Emily Cope<sup>1, 2</sup>, Sati Gurel<sup>2</sup>, Andres Traslosheros<sup>2</sup>, Amber Kenny<sup>1</sup>,

<sup>2</sup>, Nimesh Mody<sup>1</sup>, Mirela Delibegovic<sup>1</sup>, Sam Philip<sup>3</sup>, Frank Thies<sup>2</sup>, Dimitra Blana<sup>4</sup>, Brendan M.
 Gabriel<sup>1, 2, 5</sup><sup>†</sup>

- 6 1. Aberdeen Cardiovascular and Diabetes Centre, Institute of Medical Sciences, School of
- 7 Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.
- 8 2. The Rowett Institute, School of Medicine, Medical Sciences & Nutrition University of
- 9 Aberdeen, Aberdeen, UK.
- 10 3. Grampian Diabetes Research Unit, Diabetes Centre, Aberdeen Royal Infirmary,
- 11 Aberdeen, UK
- 12 4. Centre for Health Data Science, Institute of Applied Health Sciences, University of
- 13 Aberdeen, Aberdeen, UK.
- 14 5. Department of Physiology and Pharmacology, Integrative Physiology, Karolinska Institute,
- 15 Stockholm, Sweden
- 16
- 17 <sup>†\*</sup>Corresponding author Dr B.M. Gabriel, P: The Rowett Institute, University of Aberdeen,
- 18 Ashgrove Rd W, Aberdeen AB25 2ZD, Aberdeen, UK. E: <u>Brendan.gabriel1@abdn.ac.uk</u>
- 19 Brenda J. Pena Carrillo ORCID-0000-0001-8975-8798 20 Emily Cope ORCID-0000-0003-3912-6287 21 Sati Gurel ORCID-0000-0001-5084-180X 22 Andres Traslosheros ORCID-0000-0003-1504-4092 23 Amber Kenny ORCID-0009-0000-1993-0038 24 Nimesh Mody ORCID-0000-0002-2215-7952 25 Mirela Delibegovic ORCID-0000-0001-6193-3152 26 Sam Philip ORCID-0000-0001-6164-211X 27 Frank Thies ORCID-0000-0002-9275-9713 **Dimitra Blana** ORCID-0000-0003-0488-6120 28 ORCID -0000-0001-6878-8779 29 Brendan M. Gabriel
- 30 Word count: 4686

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 31 Abstract

32 Exercise is recommended in the treatment of Type 2 Diabetes and can improve insulin sensitivity [1]. However, previous evidence suggests that exercise at different times of the day 33 34 in people with type 2 diabetes may have opposing outcomes on glycaemia [2]. Metformin is 35 the most commonly prescribed initial pharmacological intervention in Type 2 Diabetes, and may alter adaptions to exercise [3]. It is unknown if there is an interaction between metformin 36 37 and diurnal exercise outcomes. We aimed to investigate glycaemic outcomes of moderate 38 intensity morning vs. evening exercise in people with type 2 diabetes being prescribed 39 metformin monotherapy. We hypothesised that evening exercise would be more efficacious 40 than morning exercise at lowering glycaemia.

41 In this study, nine male and nine females with type 2 diabetes undergoing metformin 42 monotherapy (age 61±2 year, mean±SEM) completed a 16-week crossover trial including 2-43 week baseline recording, six weeks randomly assigned to a morning exercise (7-10am) or 44 evening exercise (4-7pm), and a two-week wash-out period. Exercise arms consisted of 30 45 minutes of walking at 70% of estimated max-HR every other day. Glucose levels were 46 measured with continuous glucose monitors and activity measured by wrist-worn monitors. Food-intake was recorded by 4-day food diaries during baseline, first and last 2 weeks of each 47 48 exercise arm.

49 There was no difference in exercise intensity, total caloric intake, or total physical activity 50 between morning and evening arms. Acute glucose area under the curve (AUC), was lower 51 (p=0.02) after acute morning exercise (180.6±16.1 mmol/L) compared to baseline (210.3±18.0 52 mmol/L). Acute AUC glucose was significantly lower (p=0.01) in participants taking metformin 53 before breakfast (152.5±10.59 mmol/L) compared with participants taking metformin after breakfast (227.2±27.51 mmol/L) only during the morning exercise arm. During weeks 5-6 of 54 55 the exercise protocol, AUC glucose was significantly lower (p=0.04) for participants taking metformin before breakfast (168.8±5.6), rather than after breakfast (224.5±21.2) only during 56 57 morning exercise.

58 Our data reveal morning moderate exercise acutely lowers glucose levels in people with type 59 2 diabetes being prescribed metformin. This difference appears to be driven by individuals 60 that consumed metformin prior to breakfast rather than after breakfast. This beneficial effect 61 upon glucose levels of combined morning exercise and pre-breakfast metformin persisted 62 through the final two weeks of the trial. Our findings suggest that morning moderate intensity 63 exercise combined with pre-breakfast metformin intake may benefit the management of 64 glycaemia in people with type 2 diabetes.

65

### 66 Keywords

67 Chronobiology, Chrono-medicine, Circadian, Exercise, Lifestyle, Metformin, Physical activity,

68 Time-of-day, Walking

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 69 **Research in Context**

- 70 What is already known about this subject?
- Exercise at different times of the day in people with Type 2 Diabetes has opposite outcomes on glycaemia.
- Metformin interferes with the glucose-lowering effect of acute exercise.
- It is unknown if there is an interaction between metformin intake timing and diurnal exercise outcomes.
- 76 What is the key question?
- Is it possible to optimise timing of concomitant metformin and exercise in people with
   Type 2 Diabetes?
- 79 What are the new findings?
  - Morning moderate exercise acutely lowers glucose levels in people with Type 2 Diabetes being prescribed metformin.
- This difference appears to be driven by individuals that consumed metformin prior to breakfast rather than after breakfast.
- Morning exercise combined with pre-breakfast metformin persistently reduced glucose compared to morning exercise combined with post-breakfast metformin through the final week (week 6) of the intervention.
- 87 How might this impact on clinical practice in the foreseeable future?
- Our study suggests it may be possible to make simple changes to the time that people with Type 2 Diabetes take metformin and perform exercise to improve their blood glucose.
- 91

80

81

## 92 Abbreviations

- 93 BIOSS: Biomathematics and Statistics Scotland
- 94 CGMs: Continuous glucose monitors
- 95 CONSORT: Consolidated Standards of Reporting Trials
- 96 GP: General Practitioner
- 97 HIIT: High intensity interval training
- 98 IRAS: Integrated Research Application System
- 99 MCTQ: Munich Chronotype Questionnaires
- 100 OCT: Renal organic cation transporter
- 101 REC: Research Ethics Committee
- 102 REM: Rapid eye movement
- 103 RPF: Renal plasma flow
- 104 SEM: Standard error of mean
- 105 SPCRN: Scottish Primary Care Research Network
- 106 Max-HR: Maximum heart rate

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 107 **1. Introduction**

Type 2 Diabetes Mellitus is a growing, global health challenge [4]. Exercise is often 108 recommended by front-line clinicians as a potent therapeutic treatment in people with type 2 109 diabetes which can improve insulin sensitivity [1]. However, little is known regarding the 110 optimal time of day to perform exercise for people with Type 2 Diabetes. Previous evidence 111 suggests that morning high intensity interval training over two weeks increases blood glucose 112 113 levels in people with type 2 diabetes [2], drawing parallels to the dawn phenomenon. 114 Conversely, evening exercise reduced glycaemia on the day of exercise in people with type 2 diabetes [2]. These apparently divergent outcomes of morning vs. evening exercise highlight 115 116 that it is imperative to optimise the timing of exercise for people with type 2 diabetes.

Several other studies have assessed the time-of-day effect of exercise upon glycaemic or 117 118 insulin-related outcomes. For example, cross-sectional data in 775 participants demonstrates 119 that moderate-to-vigorous exercise in the afternoon or evening was associated with a greater 120 reduction of insulin resistance compared with an evenly distributed daily time-pattern of exercise [5]. Further associative evidence [6], demonstrates that in 2,416 participants that 121 122 moderate-to-vigorous physical activity performed in the afternoon is associated with improvements in glycaemic control in people with diabetes. In a randomised trial, men who 123 were overweight or obese demonstrated improvements in glycaemic control after evening 124 125 exercise, while a group who exercised in the morning saw no improvements in glycaemic 126 control [7]. In another randomised trial assessing people with compromised metabolism, a 127 group that performed exercise training in the evening experienced superior beneficial improvements in fasting plasma glucose levels compared to a group that performed exercise 128 training in the morning [8]. Skeletal muscle is key in the metabolic response to exercise [1] 129 130 and it has been demonstrated that people with type 2 diabetes have an intrinsically altered circadian rhythm in skeletal muscle, both at the level of the molecular clock, and of 131 132 mitochondrial function [9]. Therefore, it is not clear whether the divergent time-of-day effect of 133 exercise on glycaemic regulation is due to an intrinsic metabolic disruption, or whether this 134 phenomenon will persist in people who are metabolically healthy. Indeed, glycaemic regulation does not appear to be different in metabolically healthy participants between a single bout of 135 morning or afternoon exercise [10]. 136

Metformin is the most commonly prescribed initial pharmacological intervention in type 2 137 diabetes and is known to alter skeletal muscle mitochondrial adaptions to exercise [3]. Further, 138 139 it has been suggested that metformin may interfere with the glucose-lowering effect of acute exercise [11, 12]. However, it is unclear whether there is an interaction between metformin 140 141 and exercise at different times of the day. Optimising exercise timing in people with type 2 142 diabetes is critically important, but also is to understand any interactions with widely prescribed pharmacological treatments. Furthermore, previous trials [2, 13] in people with type 2 diabetes 143 have not assessed whether compensatory physical activity, altered diet, or changed sleeping 144 patterns underlie any time-of-day exercise effect. In this 16-week randomised crossover study, 145 146 we aimed to investigate glycaemic outcomes of moderate intensity exercise at different times of the day in people with type 2 diabetes also being prescribed metformin monotherapy. 147 148 Secondary outcomes included total physical activity, medication timing, diet, and sleep. Based 149 on previous evidence [2, 5-8], we hypothesised that evening exercise would be more efficacious in lowering glycaemia in the trial. 150


## 151 2. Methods

# 152 **2.1. Study Design & Ethical approval**

The study was conducted following ethical approval from the UK Health Research Authority'sIntegrated Research Application System (IRAS), and via the London Centre Research Ethics

medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295059; this version posted September 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Committee (REC reference: 20/PR/0990; IRAS project ID: 292015) and in accordance with 155 the principles of the Declaration of Helsinki as revised in 2008. Informed written consent was 156 obtained from participants during recruitment. The trial was preregistered - Research Registry 157 158 Unique Identifying Number: researchregistry6311. Nine males and nine females with type 2 diabetes also being prescribed metformin monotherapy completed a remote, randomised, 159 160 crossover two-arm trial. An overview of the study's design is shown in Figure 1.



162 Figure 1. Study Design. HR, Heart rate. Figure created with Biorender.

#### 163 2.2. Participants

161

#### 2.2.1. Eligibility criteria 164

To be considered eligible for inclusion, participants had to be diagnosed with type 2 diabetes 165 (insulin independent); have a body Mass Index of 20-36 kg/m<sup>2</sup>; aged 45-75 years, male or 166 female; be prescribed metformin; be able to participate in an exercise intervention; be able to 167 168 interact with smart-phone apps and be able to provide informed consent. Participants were excluded from the study if they were treated with insulin medication; they were current nicotine 169 users (cigarettes/nicotine gum etc.); they were past nicotine users <6 months before inclusion 170 171 in the study; have a pre-existing cardiovascular condition; pre-existing blood-borne disease; 172 pre-existing rheumatic illness; have cancer; have a pre-existing psychiatric disorder; another pre-existing systemic disease; extreme chronotype (e.g., extreme 'lark' or 'owl'); prescribed 173 any glycaemia regulating medications other than metformin; already meeting physical activity 174 guidelines *i.e.* > 150 minutes of moderate intensity activity a week or 75 minutes of vigorous 175 176 intensity activity a week or those who could not adequately read or understand English.

#### 177 2.2.2. Recruitment

Volunteers were recruited from the Aberdeen and Aberdeenshire areas through the Scottish 178 Primary Care Research Network (SPCRN), over the course of 1 year, between May 2021 and 179 180 June 2022. The experimental study included recruitment and exercise interventions for two medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295059; this version posted September 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

groups, winter, and summer cohort. SPCRN conducted a pre-screening and eligible potential 181 volunteers received a letter of invitation from their National Health Service GP practice. If 182 individuals were interested in participating, they were sent the consent form and 183 184 questionnaires as part of an information pack. After phone consultation, participants who agreed to continue were instructed to complete, sign and to mail the forms back to the research 185 team. Following a review of the forms to ensure they were properly completed; the necessary 186 equipment was posted to the participants. Subsequently, participants received another phone 187 call from a member of the research team to review the participant information sheet (PIS), 188 189 answer any questions the participant may have and explain the instructions on how to fit 190 continuous glucose monitors and physical activity monitors.

191 GPs were notified about their patient's participation in the study and the researchers were sent participants' information about BMI, HbA1c, date of type 2 diabetes diagnosis, and time since 192 metformin prescription from the GP records. One participant did not have any available data, 193 five of the participants did not have available records about type 2 diabetes diagnosis date 194 195 and four participants time since metformin prescription as they were new to the GP.

#### 196 2.2.3. Sample size calculation

The number of participants (30) was determined in collaboration with an independent 197 statistician at Biomathematics and Statistics Scotland (BioSS) based on our previous study 198 199 [2]. *i.e.* an estimated difference in mean glucose concentration of 0.69 mmol/L, an estimated standard deviation (SD) of 1.32 mmol/L (SD of the individual differences between two exercise 200 201 treatments), a paired analysis, a significance level of 0.05 and a power of 80%.

202 2.2.4. Randomization to morning or evening exercise

203 Randomisation was carried out by an independent statistician at BioSS. Microsoft Excel was used to randomly allocate participants to the two possible sequences (*i.e.*, morning first or 204 evening first) in blocks by order of joining the trial and sex. The randomisation was generated 205 206 once we received a positive response from the participant.

#### 2.2.5. Adherence monitoring 207

Compliance with the exercise regimen were assessed using real-time data obtained from the 208 209 Garmin Connect (Garmin Ltd, Olathe, KS, US) and LibreView (Abbott Diabetes Care Inc, Alameda, CA, US) sites. Participants missing pre-defined adherence targets (*i.e.*, either 210 missing >4 exercise windows in less than 2 weeks, with a heart rate discrepancy of >15%211 212 during exercise or >4 days with no glucose reading) were contacted by phone call or e-mail and encouraged to improve adherence. If adherence was not improved, they were not 213 214 considered for the final data analysis. When the trial coincided with the Christmas holidays, the wash-out period was extended for a period of 4 weeks so that the intervention arms did 215 not run during the Christmas holidays. 216

#### 2.3. Exercise Intervention 217

Participants were requested to perform 30 minutes of walking every other day during a 6-week 218 period, maintaining, as close as possible, 70% of their estimated maximum heart rate 219 220 (estimated with the formula 220 minus age [14]) during exercise. Participants were instructed 221 to perform exercise within a 3-hour window between either 7:00-10:00 AM or 4:00- 7:00 PM. The overall 16-week trial period included 2-week baseline recording, 12-week intervention 222 arms (6 weeks morning and then 6 weeks evening exercise, or vice versa) with a 2-week 223 washout between trial arms. Physical activity data were collected for the entirety of the trial, 224 225 pre-trial and wash-out period.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 226 **2.4. Outcomes**

## 227 **2.4.1. Physical activity**

Physical activity data (assessed as step count per day and heart rate) as well as sleep quality were collected via a wrist-based physical activity monitor Garmin Vivosmart 4 (Garmin Ltd, Olathe, KS, US), which participants were asked to wear for the entire duration of the trial. Participants were instructed to download the Garmin Connect application and log in with a study password. The outcomes of the physical activity monitors were step count per day, heart rate and sleep quality. Participant's chronotype was determined using the self-report Munich Chronotype Questionnaire.

## 235 2.4.2. Glucose monitoring

Participants were provided with continuous glucose monitors The FreeStyle Libre 2 sensor 236 (CGMs, Abbott Diabetes Care Inc, Alameda, CA, US), that measures the glucose 237 238 concentration in interstitial fluid continuously, storing a reading every 15 minutes. Sensors had a working life of 2-weeks. Glycaemia data was collected by the LibreView (Abbott Diabetes 239 Care Inc, Alameda, CA, US) cloud system, participants were instructed to download the 240 241 FreeStyle LibreLink application on their own smart phones to share and link their data to a 242 LibreView account in real time. Glucose information was collected for 2 weeks before start of 243 the intervention, during the first 2 weeks, and for the last two weeks of each exercise 244 intervention.

## 245 2.4.3. Dietary Intake and metformin dose

Participants were asked to maintain their normal diet consistently throughout the trial and 246 record their diet throughout the trial using a 4-day food diary in which the participant recorded 247 248 the food eaten, the time of day each meal was consumed, the cooking methods used, and the portion sizes. A 4-day food diary was completed during the baseline period, and during the 249 250 first 2 weeks, and the last 2 weeks of each exercise intervention. Dietary intake was determined using Windiet software (Univation Ltd, The Robert Gordon University, Aberdeen, 251 Scotland, UK). Participants were also asked to record the time and dose of metformin on their 252 food diaries. As dietary intake and metformin time and dose were self-reported, the data 253 analysis of the food diaries and metformin time-doses corresponded to 14 participants and the 254 metformin analysis is from 13 participants that fulfilled this requirement. 255

## 256 **2.5. Data analysis**


Blood glucose levels were measured using CGMs, from which 24-hours hourly mean were 257 calculated using the R Studio statistical software package v2022.12 (Rstudio.com; R version 258 259 4.2.2, R Foundation for Statistical Computing, Boston, MA, US). Data was then analysed using Prism 9.5.1 software (GraphPad, San Diego, CA, US) by One-way ANOVA or two-way 260 ANOVA followed up by Holm-Šídák's multiple comparisons test (significance level set at 261 p < 0.05). Baseline characteristics between males and females were compared by means using 262 t-test (significance level set at p < 0.05). Results are expressed as Mean±SEM and estimates 263 with 95% Cls. 264

## 265 **3. Results**

## **3.1. Participants recruitment and characteristics.**

Of the forty positive responses received, nine male and nine females with type 2 diabetes being prescribed metformin completed the 16-week crossover intervention; see Figure 2 for consolidated Standards of Reporting Trials (CONSORT) flow chart. Following randomization, eight participants withdrew for personal reasons, four of them from the winter cohort and four medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295059; this version posted September 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

271 from summer group. After completion of the trial, five participants did not meet the exercise intervention requirements, finishing with eleven participants from winter; and seven from the 272 summer cohort. In terms of crossover sequence, the study finished with eight participants who 273 did morning exercise first and ten participants who did evening exercise first. Sleep data 274 corresponds to fifteen participants who fulfilled this requirement, glucose data was missing 275 from one participant during the last 2 weeks of the morning period and from two participants 276 during the last 2 weeks of evening exercise. Baseline characteristics of study participants that 277 completed the trial are shown in Table 1 (Characteristics according to different stratification 278 are shown in supplementary Tables 1,2,3,4,5). 279



280

Figure 2. Consolidated Standards of Reporting Trials (CONSORT) flow chart. 281

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

282 Table 1. Baseline characteristics of study participants.


Characteristic (n = 18)	Mean ± SEM
Sex	Male n=9; Female n=9
Age (years)	61±2
BMI (Kg/m²)	30.6±0.7
HbA1c (mmol/mol)	64.4±15.0
HbA1c (%)	8.0±0.3
Time since T2D diagnosed (years) Dose of Metformin per day (mg)	8.2±1.7 1313.0±134.6
Time of Metformin (years)	5.2±1.0
Steps per day at baseline	6798±595

283 T2D, Type 2 Diabetes

### **3.2.** Adherence to exercise intervention.

The total number of exercise sessions participants were asked to complete during each 285 exercise period was 21. The exercise completion rate was consistent (p=0.47) between 286 morning (19.1±1.3 sessions) and evening exercise (18.1±1.4 sessions) (Supplementary 287 Figure 1). Total physical activity was similar between the arms of the trial (Figure 3A, B). The 288 289 number of mean daily steps recorded during baseline was 6798.0±595.6. During exercise 290 days participants completed a mean daily total of 10814.0±530.7 steps and 10373.0±514.6 steps during morning and evening, respectively (p=0.15). During rest days participants 291 292 completed a mean daily total of 6843.0±561.8 steps and 6344.0±514.3 steps during morning 293 and evening, respectively (p=0.24). Total hours of sleep registered from Garmin devices  $(8.3\pm0.3)$  was significantly higher (p=0.03) the hours of sleep recorded from self-reported 294 MCTQ (7.67±0.2) (Supplementary Figure 2). The total hours of sleep indicated a trend (one-295 way ANOVA: p=0.06) showing longer sleep duration during evening exercise (8.3±0.2 hours) 296 297 compared with morning exercise (7.9±0.2 hours), however there was no difference compared with baseline (*p*=0.31, *p*=0.40, morning exercise, evening exercise, respectively) (Figure 3C). 298 299 Sleep architecture such as deep sleep, light sleep, REM sleep and time awake showed no 300 significant difference between baseline, morning and evening exercise (p=0.35, p=0.57, p=0.06, p=0.20, respectively) (Supplementary Figure 3). Participants were instructed to 301 exercise at an estimated 70% of max-HR, which was 111.4±1.3 bpm. Exercise intensity during 302 morning and evening exercise was similar (Figure 3D), as measured by HR (117.2±1.9 bpm 303 304 and 117.3±2.7 bpm, respectively, p=0.93). Overall, our results show no differences in physical activity or compensatory activity between morning and evening exercise. 305

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




306

Figure 3. Step count, max-HR and total sleep hours during the morning and evening exercise periods. The values are shown for number of steps on (A) Days when the participants performed exercise (n=18) and (B) Rest days (n=18); (C) Total sleep hours during exercise (n=15) and (D) Max-HR (n=18) throughout trial; blue lines are mean±SEM, dotted line (Figure D) represents 70% Max-HR estimated; HR, Heart rate. Step count, total hours of sleep and sleep insights were analysed using one-way ANOVA, total hours of sleep from Garmin devices vs MCTQ and Max-HR were analysed using paired t-test.

### **3.3. Changes in glucose during exercise intervention**


There was a significant decrease (p=0.02) in acute (first 24 hours of exercise) AUC glycemia during morning exercise (180.6±16.1 mmol/L) compared with baseline (210.3±18.0 mmol/L), whereas there were no significant differences in acute glycemia levels during evening exercise compared with baseline (p=0.12). No change in acute glucose levels between morning and evening exercise were observed (p=0.14) (Figure 4A). An hour-by-hour time-course of glucose readings did not indicate a difference in glycemia during the trial (p>0.05) (Figure 4B). medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295059; this version posted September 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .



321

Figure 4. Acute 24-hour glucose levels. (A) Area under the curve (AUC) values for glucose 322 levels during the first 24 hours of exercise. (n=18) (B) Time-course plot hourly glucose levels 323 for the first 24 hours of exercise during baseline, morning, and evening intervention (n=18). 324 Wk, week. \*p< 0.05. Values are mean±SEM, lines represent individual values. Data were 325 analysed using one-way ANOVA followed up by Holm-Šídák's multiple comparisons test. 326

24-hour AUC glucose during baseline (210.3±18.0 mmol/L), morning (197.3±13.9 mmol/L) 327 328 and evening (206.7±14.9 mmol/L) during weeks 1-2 did not differ significantly (p=0.24) (Figure 5A). Further, no difference in glucose concentration was observed at any time point during the 329 24-hour time-course between baseline, morning, and evening exercise, during weeks 1-2 330 331 (Figure 5B). Similar findings were observed at weeks 5-6 (Figure 5D).



332

Figure 5. 24-hour glucose levels in response to exercise intervention. (A) Area under the curve 333 (AUC) 24-hour glucose for week 1-2 of exercise intervention (n=18) (B) Time-course plot 24-334 hour glucose in weeks 1-2 (n=18) (C) Area under the curve (AUC) 24-hour glucose for week 335 336 5-6 of exercise intervention (n=17) (D) Time-course plot 24-hour glucose in weeks 5-6 (n=17). Wk, week. Values are mean±SEM, lines represent individual values. Data were analysed 337 using one-way ANOVA followed up by Holm-Šídák's multiple comparisons test. 338


No significant interaction effect was observed for sex x time of the exercise (Supplementary 339 Figure 4). There was a trend (p=0.07) showing lower AUC glucose levels in summer 340

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

341 (222.4 $\pm$ 6.1) compared to the winter (169.8 $\pm$ 0.9). This consistent pattern persisted throughout 342 the entire intervention period, however, this difference in AUC glucose levels between winter 343 and summer did not reach statistical significance (*p*=0.07) (Supplementary Figure 5).

### **344 3.4. Caloric intake during exercise intervention**

There were no changes in dietary energy intake during breakfast (p=0.30), baseline 345 (390.5±38.2 Kcal), morning weeks 1-2 (355.0±22.8 Kcal), evening weeks 1-2 (353.1±49.6 346 Kcal), morning weeks 5-6 (311.6±27.21 Kcal), evening weeks 5-6 (354.2±40.71 Kcal) 347 throughout the trial (Figure 6A). Energy intake during lunch was significantly different (p=0.03) 348 between morning weeks 1-2 (534.3±61.0 Kcal) and evening weeks 5-6 (402.7±45.5 Kcal) 349 350 (Figure 6B). However, no significant differences were observed (p=0.64) when comparing evening weeks 5-6 with the energy intake at baseline (470.4±41.3 Kcal). There was no 351 352 difference in caloric ingestion of dinner (p=0.14) (Figure 6C) between arms of the trial. No 353 changes in caloric intake were detected between comparable periods of the trial.




#### 354

Figure 6. Mean caloric intake during exercise intervention. Data collected from self-reported 4-days food diaries for (A) Size of breakfast (n=14), (B) Size of lunch (n=14) and (C) Size of dinner (n=14). Values are mean±SEM. Data were analysed using one-way ANOVA followed up by Holm-Šídák's multiple comparisons test.

There were no differences (p=0.33) in total daily caloric intake consumed during baseline (570.6±142.1 Kcal), morning weeks 1-2 (573.3±149.9 Kcal), evening weeks 1-2 (533.1±116.8 Kcal), morning weeks 5-6 (585.2±165.6 Kcal) and evening weeks 5-6 (545.2±167.3 Kcal) (Figure 7). Throughout the trial, caloric intake was significantly higher (p=<0.001) during dinner (843.1±23.8 Kcal), compared with breakfast (349.0±13.0 Kcal) and lunch (492.4±27.3 Kcal).

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .




364

Figure 7. Total daily caloric intake. Data collected from self-reported 4-days food diaries from baseline (n = 14), morning weeks 1-2 (n = 14), evening weeks 1-2 (n=15), morning weeks 5-6 (n=14), evening weeks 5-6 (n=13). Values are mean±SEM. Data were analysed using oneway ANOVA followed up by Holm-Šídák's multiple comparisons test.

### 369 3.5. Meals and metformin timing

Acute 24 AUC glucose was lower (p=0.01) in participants taking metformin before breakfast (152.5±10.6 mmol/L) compared with participants taking metformin after breakfast (227.2±27.5 mmol/L) only when the participants performed morning exercise (Figure 8B). No differences were observed for metformin before or after breakfast for the baseline and evening exercise arms of the trial (p=0.17 and p=0.67, respectively), nor for metformin before or after dinner during baseline, or morning or afternoon exercise (p=0.44 and p=0.25, respectively) (Supplementary Figure 6).




377

Figure 8. Meal and metformin timing. Area under the curve (AUC) values for glucose levels
during the first 24 hours of exercise for (A) Baseline, metformin pre-breakfast (n=9), metformin
post-breakfast (n=5); (B) Morning exercise, metformin pre-breakfast (n=8), metformin postbreakfast (n=5); (C) Evening exercise, metformin pre-breakfast (n=10), metformin postbreakfast (n=4). \*p< 0.05. Values are mean±SEM. Data were analysed using unpaired t-test.</li>

During morning exercise (weeks 1-2), participants taking metformin before breakfast exhibited a trend (p=0.07) to have lower AUC glucose levels (165.4±3.3 mmol/L) compared with

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

participants taking metformin after breakfast (223.3 $\pm$  25.1 mmol/L) (Figure 9). During weeks 5-6 of the exercise protocol, glucose was significantly lower (p=0.04) for participants taking metformin before breakfast (168.8 $\pm$ 5.6), rather than after breakfast (224.5 $\pm$ 21.2) only during morning exercise. No differences in AUC glucose for metformin before/after breakfast were observed for the evening arm of the trial throughout the protocol (evening arms, weeks 1-2, p=0.80, weeks 5-6 p=0.72).



391

Figure 9. Meal and metformin timing throughout the trial. Area under the curve (AUC) values 392 for glucose levels for Baseline period, metformin pre-breakfast (n=9), metformin post-393 breakfast (n=5); Morning exercise (weeks 1-2), metformin pre-breakfast (n=8), metformin 394 395 post-breakfast (n=6); Evening exercise (weeks 1-2), metformin pre-breakfast (n=10), 396 metformin post-breakfast (n=4); Morning exercise (weeks 5-6), metformin pre-breakfast (n=8), 397 metformin post-breakfast (n=6); Evening exercise (weeks 5-6), metformin pre-breakfast (n=9), metformin post-breakfast (n=4). \*p< 0.05. Values are mean±SEM. Blue dots are participants 398 that changed metformin intake timing between different periods of the trial, lines represent 399 400 individual crossover values. Data were analysed using two-way mixed-model ANOVA followed up by Holm-Šídák's multiple comparisons test. 401

## 402 4. Discussion

These data demonstrate that morning moderate intensity exercise acutely reduces glycaemia 403 404 in people with type 2 Diabetes also being prescribed metformin. While evening exercise had no effect upon glycaemia. The acute reduction of glycaemia in the morning trial was apparently 405 406 driven by people who consumed metformin before breakfast, rather than after breakfast. Indeed, morning exercise combined with pre-breakfast metformin persistently reduced AUC 407 glucose compared to morning exercise combined with post-breakfast metformin up to the final 408 week (week 6) of the intervention. In this crossover trial, there was no significant difference in 409 410 exercise intensity, caloric intake or total physical activity between the arms of the trial (morning vs evening exercise). These findings support the assertion that an interaction with intrinsic 411 412 circadian biology may be linked to the observed effects.

Interestingly, we observed that the acute morning exercise decrease in glycaemia was apparently driven by people who consumed metformin before breakfast rather than after breakfast. Many people taking metformin struggle to maintain regular physical activity [15], which may be a result of a lower tolerance of exercise when metformin is concomitant [16].

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

417 Furthermore, metformin may interfere with the glucose-lowering effect of acute exercise [11, 12]. Therefore, identifying strategies to optimise concomitant prescription of these therapies 418 is essential. Our data suggests that it may be possible to optimise timing of these concomitant 419 420 therapies to augment their therapeutic effect. It should be noted that these specific data in the 421 current study are not crossover, however, the magnitude of difference (33% decreased AUC 422 glucose in pre-breakfast group, Figure 8) suggests a real effect. Additionally, an interaction effect on glycaemia between morning exercise and pre-breakfast metformin intake appeared 423 424 to persist throughout the trial since the group taking metformin before breakfast had lower AUC glucose than the post breakfast group into week 6 of the morning exercise intervention. 425 426 These findings have parallels to previous data that suggest consuming metformin before a meal improved efficacy upon glycaemic regulation [17]. This effect on glycaemia may be partly 427 428 related to metformin's pharmacokinetic interaction with meal intake and intrinsic circadian 429 rhythms. For example, compared with the fasting state, bioavailability of metformin is 24% 430 lower, and the peak concentration delayed about 37 min when an 850 mg tablet is 431 administered with food [18]. Additionally, metformin's pharmacology significantly depends on time-of-day in humans, which may be related to glomerular filtration rate, renal plasma flow 432 (RPF) and renal organic cation transporter (OCT) 2 activity [19]. Although the half-life of 433 434 metformin in the blood is relatively long (~18 hours depending on dose/method [20]), less is known regarding accumulation in skeletal muscle, a key organ in the response to exercise [1]. 435 It is known that concomitant exercise alters the pharmacokinetics of acute metformin 436 administration [16, 20], with differing skeletal muscle concentrations of metformin before, 437 438 during and after exercise [16]. It is plausible then, that exercise at different times of the day in 439 addition to timing of metformin intake may interact with the pharmacokinetics and glycaemic modulating effects of metformin. This is supported by our findings since we observed a 440 glucose lowering effect of pre-breakfast metformin only during morning exercise periods of the 441 442 trial. Thus, further research should aim to fully elucidate the interaction between meal-timing, exercise and medication intake. 443

As described above, skeletal muscle plays a key role in the metabolic response to exercise, 444 445 and this organ has an intrinsically disrupted rhythm in people with type 2 Diabetes [9]. However, it is plausible that metformin treatment may interact with skeletal muscle circadian 446 metabolism to alter time-of-day exercise effects observed in other studies in people with 447 448 impaired metabolism. Supportive of this is the lack of effect upon glycaemia in response to exercise at different times of the day in people who are metabolically healthy [10] and who 449 450 presumably do not have disrupted metabolic circadian rhythms. However, the aforementioned 451 study [10] only monitored response to a single bout of exercise, while the current study was a 16-week trial in which participants did two 6-week training periods. Moderate intensity exercise 452 453 did not increase glycaemia in people with type 2 Diabetes being prescribed metformin. These 454 data indicate that in terms of glycaemic response, morning moderate intensity exercise is not deleterious in people with type 2 diabetes being prescribed metformin and does not 455 456 exacerbate the dawn phenomenon in the same manner as HIIT [2].

Indeed, exercise modality may interact with circadian rhythm to alter exercise outcomes. High-457 intensity exercise capacity is consistently higher in the afternoon/evening compared to 458 459 morning, while diurnal differences in exercise capacity are less clear with moderate intensity 460 exercise [21]. This phenomenon may underlie the findings of Teo et al. (2020), who found no time-of-day differences in glycaemic outcomes in people with type 2 diabetes in response to 461 combined walking exercise and resistance training [13]. This exercise modality [13] contrasts 462 with the HIIT protocol used in previous studies with conflicting findings [2]. However, it should 463 be noted that Teo et al. (2020) did not measure glycaemic outcomes in a circadian manner 464 465 [13]. Whereas, in the current study we have measured 24-hour glucose over a total period of 466 10-weeks. Additionally, participants completed moderate intensity exercise outdoors in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

467 Scotland, which may influence diurnal outcomes compared to exercise protocols completed 468 at a higher intensity or in a different environment. In a laboratory setting, fifty minutes of 469 walking at 3 different times of day and at different timing in relation to meals did not lower 24-470 hour glucose concentrations in people with type 2 diabetes [22]. Together with the results from 471 the current study, these data suggest that moderate intensity exercise may not give rise to 472 time-of-day dependent glycaemic perturbations of the same magnitude as high intensity 473 exercise.

The current study had some limitations. Our prior statistical power calculations suggested a 474 sample size of 30 in order to detect differences in hour-by-hour glucose readings. Although 475 476 we met our recruitment target, we had a higher-than-expected withdrawal rate, with 18 477 participants eligible for final analysis. We conducted this study mainly during the C-19 global 478 pandemic, which directly and indirectly impacted on participants' ability to complete the 16week trial. Nevertheless, the strength of our study is the cross-over design, giving greater 479 statistical power than a cross-sectional design. We aimed to recruit people with type 2 diabetes 480 481 who were being prescribed metformin monotherapy, *i.e.* no other glycaemic regulating pharmaceutical treatments. This criterium allowed us to investigate a time-of-day exercise 482 interaction with metformin treatment specifically, rather than being confounded by other 483 pharmaceutical treatments. As previously noted, metformin timing intake was not a primary 484 485 outcome of this study, and therefore our comparisons between different metformin intake 486 timings are not crossover. Thus, it is possible that existing differences in glycaemic regulation 487 between groups are responsible for some of the observed differences (e.g. Supplementary 488 table 4). However, it is likely that metformin intake timing is highly habitual, and it is plausible 489 that participants who habitually take metformin before breakfast may experience better longterm control of glycaemia as a direct result. A further strength of the study was the excellent 490 adherence of participants to the exercise protocol, with >85-90% exercise session completion 491 rate over 6-weeks and no difference in self-monitored exercise intensity between arms of the 492 493 trial. The advantage of conducting self-monitored exercise trials is that this is likely to better recapitulate many real-world settings in which clinicians' recommendations to exercise are 494 495 mostly self-monitored rather than monitored by practitioners. Participants were instructed to 496 maintain their normal diet during the trial, and total caloric intake was not different between 497 arms of the trial, indicating adherence to this instruction. However, it should be noted that 498 dietary intake was self-reported.

499 In summary, our study demonstrates an acute decrease in glycaemia in response to morning exercise in people with type 2 diabetes also being prescribed metformin. The reduction of 500 glycaemia was driven by participants who consumed metformin before breakfast, rather than 501 502 after breakfast, indicating an interaction between meal-timing, metformin intake and exercise. In this trial we monitored diet, exercise intensity, and physical activity throughout the trial, none 503 504 of which appeared to contribute to the time-of-day dependent effect of exercise on glycaemia. Many people being prescribed metformin struggle to maintain regular physical activity [15], 505 and metformin may interfere with the glucose-lowering effect of acute exercise [11, 12]. Thus, 506 507 finding strategies to augment the therapeutic effect of these treatments when concomitant is essential in the management of type 2 diabetes. Our research indicates that it may be possible 508 509 to optimise the timing recommendations for concomitant exercise and metformin treatment. 510 Specifically, our findings suggest that morning moderate intensity exercise combined with pre-511 breakfast metformin intake may benefit the management of glycaemia in people with type 2 diabetes. 512

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

#### 5. Acknowledgements 513

514 We would like to thank Amanda Cardy from the NRS Primary Care Network for her help in recruiting participants. We would also like to thank Dr Graham Horgan of Biomathematics & 515 516 Statistics Scotland (BIOSS) for his support with statistical analysis.

517

#### 6. Funding 518

This study was funded by a European Foundation for the Study of Diabetes/Lilly Young 519 520 Investigator Award and an NHS Grampian Endowment Research Grant, both to B.M.G. B.M.G. was also supported by a fellowship from the Novo Nordisk Foundation 521 (NNF19OC0055072). B.J.P.C. was supported by a Mexican Government CONAHCyT PhD 522 523 Studentship (CVU: 516989).

524

#### 7. Data availability 525

Raw data underlying all figures in this manuscript have been deposited publicly: 526 527 10.6084/m9.figshare.24081417

528

#### 8. References 529

- Gabriel BM, Zierath JR (2017) The Limits of Exercise Physiology: From Performance 530 1. to Health. Cell Metab. 25:1000-1011 531
- 532 2. Savikj M, Gabriel BM, Alm PS, et al (2019) Afternoon exercise is more efficacious than morning exercise at improving blood glucose levels in individuals with type 2 533 534 diabetes: a randomised crossover trial. Diabetologia 62(2):233-237. https://doi.org/10.1007/s00125-018-4767-z 535
- 3. Konopka AR, Laurin JL, Schoenberg HM, et al (2019) Metformin inhibits mitochondrial 536 adaptations to aerobic exercise training in older adults. Aging Cell 18(1):e12880. 537 https://doi.org/10.1111/acel.12880 538
- 4. Saeedi P, Petersohn I, Salpea P, et al (2019) Global and regional diabetes 539 prevalence estimates for 2019 and projections for 2030 and 2045: Results from the 540 International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract 541 157. https://doi.org/10.1016/J.DIABRES.2019.107843 542
- van der Velde JHPM, Boone SC, Winters-van Eekelen E, et al (2023) Timing of 543 5. physical activity in relation to liver fat content and insulin resistance. Diabetologia 544 66(3):461-471. https://doi.org/10.1007/S00125-022-05813-3 545
- 6. Qian J, Xiao Q, Walkup MP, et al (2023) Association of Timing of Moderate-to-546 Vigorous Physical Activity With Changes in Glycemic Control Over 4 Years in Adults 547 With Type 2 Diabetes From the Look AHEAD Trial. Diabetes Care. 548 549 https://doi.org/10.2337/DC22-2413
- Moholdt T, Parr EB, Devlin BL, Debik J, Giskeødegård G, Hawley JA (2021) The 550 7. 551 effect of morning vs evening exercise training on glycaemic control and serum metabolites in overweight/obese men: a randomised trial. Diabetologia 64(9):2061-552 2076. https://doi.org/10.1007/s00125-021-05477-5 553
- 8. Mancilla R, Brouwers B, Schrauwen-Hinderling VB, Hesselink MKC, Hoeks J, 554 555 Schrauwen P (2021) Exercise training elicits superior metabolic effects when

performed in the afternoon compared to morning in metabolically compromised 556 humans. Physiol Rep 8(24). https://doi.org/10.14814/phy2.14669 557 9. Gabriel BM, Altıntaş A, B Smith JA, et al (2021) Disrupted circadian oscillations in 558 559 type 2 diabetes are linked to altered rhythmic mitochondrial metabolism in skeletal muscle. Sci Adv 7. https://doi.org/10.1126/SCIADV.ABI9654 560 561 10. Tanaka Y, Ogata H, Park I, et al (2021) Effect of a single bout of morning or afternoon exercise on glucose fluctuation in young healthy men. Physiol Rep 9(7):e14784. 562 https://doi.org/https://doi.org/10.14814/phy2.14784 563 Boulé NG, Robert C, Bell GJ, et al (2011) Metformin and exercise in type 2 diabetes: 11. 564 examining treatment modality interactions. Diabetes Care 34(7):1469–1474. 565 https://doi.org/10.2337/DC10-2207 566 12. Sharoff CG, Hagobian TA, Malin SK, et al (2010) Combining short-term metformin 567 568 treatment and one bout of exercise does not increase insulin action in insulin-resistant 569 individuals. Am J Physiol Endocrinol Metab 298(4). https://doi.org/10.1152/AJPENDO.00517.2009 570 Teo SYM, Kanaley JA, Guelfi KJ, Marston KJ, Fairchild TJ (2020) The Effect of 13. 571 572 Exercise Timing on Glycemic Control: A Randomized Clinical Trial. Med Sci Sports 573 Exerc 52(2):323-334. https://doi.org/10.1249/MSS.000000000002139 574 14. Fox SM, Naughton JP, Gorman PA (1972) Physical activity and cardiovascular health. 575 II. The exercise prescription: intensity and duration. Mod Concepts Cardiovasc Dis 576 41(5):21-24 15. Krug LM, Haire-Joshu D, Heady SA (1991) Exercise habits and exercise relapse in 577 persons with non-insulin-dependent diabetes mellitus. Diabetes Educ 17(3):185–188. 578 579 https://doi.org/10.1177/014572179101700314 580 16. Kristensen JM, Lillelund C, Kjøbsted R, et al (2019) Metformin does not compromise energy status in human skeletal muscle at rest or during acute exercise: A 581 582 randomised, crossover trial. Physiol Rep 7(23). https://doi.org/10.14814/phy2.14307 Hashimoto Y, Tanaka M, Okada H, et al (2016) Postprandial hyperglycemia was 583 17. ameliorated by taking metformin 30 min before a meal than taking metformin with a 584 585 meal; a randomized, open-label, crossover pilot study. Endocrine 52(2):271–276. https://doi.org/10.1007/S12020-015-0786-4 586 587 18. Sambol NC, Brookes LG, Chiang J, et al (1996) Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J 588 Clin Pharmacol 42(4):510–512. https://doi.org/10.1111/J.1365-2125.1996.TB00017.X 589 590 19. Türk D, Scherer N, Selzer D, et al (2023) Significant impact of time-of-day variation on metformin pharmacokinetics. Diabetologia 66(6). https://doi.org/10.1007/S00125-023-591 592 05898-4 20. Larsen S, Rabol R, Hansen CN, Madsbad S, Helge JW, Dela F (2012) Metformin-593 treated patients with type 2 diabetes have normal mitochondrial complex I respiration. 594 595 Diabetologia 55(2):443-449. https://doi.org/10.1007/s00125-011-2340-0 596 21. Gabriel BM, Zierath JR (2019) Circadian rhythms and exercise — re-setting the clock in metabolic disease. Nat Rev Endocrinol 15(4):197-206. 597 https://doi.org/10.1038/s41574-018-0150-x 598 599 22. Munan M, Dyck RA, Houlder S, et al (2020) Does Exercise Timing Affect 24-Hour Glucose Concentrations in Adults With Type 2 Diabetes? A Follow Up to the Exercise-600 Physical Activity and Diabetes Glucose Monitoring Study. Can J diabetes 44(8):711-601

medRxiv preprint doi: https://doi.org/10.1101/2023.09.07.23295059; this version posted September 7, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

602 718.e1. https://doi.org/10.1016/J.JCJD.2020.05.012